Cisplatine Accord 1 mg/ml concentraat voor oplossing voor infusie

DRUG4 trials

Sponsors

Institut Gustave Roussy, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Universitair Ziekenhuis Gent

Conditions

FIGO stage III high grade serous ovarian cancerFIGO stage III ovarian cancer who are eligible for primary cytoreductive surgery resulting in non-residual diseaseSynchronous oligometastatic non-small cell lung cancer (NSCLC)metastatic non-small-cell lung canceror fallopian tube carcinomaor residual disease up to 2.5 mmperitoneal cancer

Phase 1

A phase 1b study of an autologous dendritic cell immunotherapy in combination with anti-programmed death-1 treatment in patients with metastatic non-small-cell lung cancer (DARE-LUNG)

Not yet recruitingCTIS2025-521577-13-00

Universitair Ziekenhuis Gentmetastatic non-small-cell lung cancer

Target: 64Updated: 2025-09-11

Phase 2

Body surface area-based vs concentration-based dosing of cisplatin for hyperthermic intraperitoneal chemotherapy (HIPEC) in women with advanced ovarian cancer (CISCON)

Active, not recruitingCTIS2024-514711-99-00

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingFIGO stage III high grade serous ovarian cancer, or fallopian tube carcinoma, peritoneal cancer

Start: 2022-05-02Target: 40Updated: 2024-06-13

Phase 3

Phase III randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy: OVHIPEC-2

Active, not recruitingCTIS2023-509049-11-00

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingFIGO stage III ovarian cancer who are eligible for primary cytoreductive surgery resulting in non-residual disease, or residual disease up to 2.5 mm

Start: 2020-01-01Target: 485Updated: 2025-07-30

First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study (OliGRAIL)

RecruitingCTIS2023-503326-39-00

Institut Gustave RoussySynchronous oligometastatic non-small cell lung cancer (NSCLC)

Start: 2025-03-06Target: 130Updated: 2025-08-26